These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

593 related articles for article (PubMed ID: 37520574)

  • 21. Treatment- and immune-related adverse events of immune checkpoint inhibitors in advanced lung cancer.
    Shao J; Wang C; Ren P; Jiang Y; Tian P; Li W
    Biosci Rep; 2020 May; 40(5):. PubMed ID: 32315071
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immune-related adverse events associated with first-line immune checkpoint inhibitors for metastatic renal cell carcinoma: A systematic review and network meta-analysis.
    Wang S; Lv H; Yu J; Chen M
    Int Immunopharmacol; 2024 Apr; 131():111884. PubMed ID: 38518592
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adverse events associated with immune checkpoint inhibitors in non-small cell lung cancer: a safety analysis of clinical trials and FDA pharmacovigilance system.
    Liang X; Xiao H; Li H; Chen X; Li Y
    Front Immunol; 2024; 15():1396752. PubMed ID: 38745663
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative safety of immune checkpoint inhibitors and chemotherapy in advanced non-small cell lung cancer: A systematic review and network meta-analysis.
    Chen CY; Huang CH; Chen WC; Huang MS; Wei YF
    Int Immunopharmacol; 2022 Jul; 108():108848. PubMed ID: 35597121
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adverse events associated with immune checkpoint inhibitors in patients with breast cancer: A systematic review and meta-analysis.
    Balibegloo M; Nejadghaderi SA; Sadeghalvad M; Soleymanitabar A; Salehi Nezamabadi S; Saghazadeh A; Rezaei N
    Int Immunopharmacol; 2021 Jul; 96():107796. PubMed ID: 34162158
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effectivity and safety of PD-1/PD-L1 inhibitors for different level of PD-L1-positive, advanced NSCLC: A meta-analysis of 4939 patients from randomized controlled trials.
    Shi Y; Duan J; Guan Q; Xue P; Zheng Y
    Int Immunopharmacol; 2020 Jul; 84():106452. PubMed ID: 32339922
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment- and immune-related adverse events of immune checkpoint inhibitors in esophageal or gastroesophageal junction cancer: A network meta-analysis of randomized controlled trials.
    Zheng J; Huang B; Xiao L; Wu M; Li J
    Front Oncol; 2022; 12():821626. PubMed ID: 36568203
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of nab-paclitaxel plus PD-1/PD-L1 inhibitor on chemorefractory relapsed small-cell lung cancer.
    Mu F; Fan B; Li H; Qin W; Wang C; Zou B; Wang L
    Future Oncol; 2023 Jun; 19(19):1367-1378. PubMed ID: 37114967
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Risk Factors for Immune Checkpoint Inhibitor-Related Pneumonitis in Cancer Patients: A Systemic Review and Meta-Analysis.
    Zhou P; Zhao X; Wang G
    Respiration; 2022; 101(11):1035-1050. PubMed ID: 36108598
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Meta-analysis of immune-related adverse events of immune checkpoint inhibitor therapy in cancer patients.
    Song P; Zhang D; Cui X; Zhang L
    Thorac Cancer; 2020 Sep; 11(9):2406-2430. PubMed ID: 32643323
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Incidence and Risk of PD-1/PD-L1 Inhibitor-associated Pneumonia in Advance Cancer Patients: A Meta-analysis].
    Chen K; Sun B
    Zhongguo Fei Ai Za Zhi; 2020 Nov; 23(11):927-940. PubMed ID: 33203196
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The determinants of very severe immune-related adverse events associated with immune checkpoint inhibitors: A prospective study of the French REISAMIC registry.
    Ruste V; Goldschmidt V; Laparra A; Messayke S; Danlos FX; Romano-Martin P; Champiat S; Voisin AL; Baldini C; Massard C; Laghouati S; Marabelle A; Lambotte O; Michot JM
    Eur J Cancer; 2021 Nov; 158():217-224. PubMed ID: 34627664
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US Food and Drug Administration adverse events reporting system.
    Zhai Y; Ye X; Hu F; Xu J; Guo X; Zhuang Y; He J
    J Immunother Cancer; 2019 Nov; 7(1):286. PubMed ID: 31694698
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The relative risk of immune checkpoint inhibitor pneumonitis in advanced non-small- cell lung cancer: Meta-analyses of controlled clinical trials.
    Kong Y; Hong L; Xu XC; Chen YF; Xu J
    PLoS One; 2024; 19(4):e0301931. PubMed ID: 38683829
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparative severe dermatologic toxicities of immune checkpoint inhibitors in malignant melanoma: A systematic review and network meta-analysis.
    Mao YT; Wang Y; Chen XX; Liu CJ; Bao Q
    J Cosmet Dermatol; 2024 Apr; 23(4):1165-1177. PubMed ID: 38013634
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Differences in the Safety and Tolerability of Immune Checkpoint Inhibitors as Treatment for Non-Small Cell Lung Cancer and Melanoma: Network Meta-Analysis and Systematic Review.
    Chai QQ; Du JY; Zhu J; Wu B
    Front Pharmacol; 2019; 10():1260. PubMed ID: 31708783
    [No Abstract]   [Full Text] [Related]  

  • 37. The effect of adding immune checkpoint inhibitors on the risk of pneumonitis for solid tumours: a meta-analysis of phase III randomised controlled trials.
    Fujiwara Y; Horita N; Namkoong H; Galsky MD
    Eur J Cancer; 2021 Jun; 150():168-178. PubMed ID: 33906099
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Patterns and outcomes of immune-related adverse events in solid tumor patients treated with immune checkpoint inhibitors in Thailand: a multicenter analysis.
    Ngamphaiboon N; Ithimakin S; Siripoon T; Sintawichai N; Sriuranpong V
    BMC Cancer; 2021 Nov; 21(1):1275. PubMed ID: 34823493
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Expression of Programmed Cell Death Ligand 1 as a Predictive Biomarker in Metastatic Urothelial Carcinoma Patients Treated with First-line Immune Checkpoint Inhibitors Versus Chemotherapy: A Systematic Review and Meta-analysis.
    Rizzo A; Mollica V; Massari F
    Eur Urol Focus; 2022 Jan; 8(1):152-159. PubMed ID: 33516645
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Risk of Pneumonitis and Pneumonia Associated With Immune Checkpoint Inhibitors for Solid Tumors: A Systematic Review and Meta-Analysis.
    Su Q; Zhu EC; Wu JB; Li T; Hou YL; Wang DY; Gao ZH
    Front Immunol; 2019; 10():108. PubMed ID: 30778352
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.